Phase II Clinical Trial Results Revealed by Healthpoint Biotherapeutics

Healthpoint Biotherapeutics today introduced that the achievements for its Phase 2b clinical trial examining the performance of HP802-247 in venous leg ulcers is posted on The Lancet, beginning August 3, 2012, with Online First access to the article, leading to print publishing within the next issue. HP802-247 is definitely an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently underneath progress regarding the remedy for venous leg ulcers.

"We are actually very happy which the trial results appear in such a prestigious standard medical journal, thus recognizing the effect chronic wounds have across a number of medical specialties," commented Bert Slade, MD, FAAAAI, Chief Medical Officer at Healthpoint Biotherapeutics.

The Phase 2b trial was created to determine the possible effectiveness of two cell amounts and a couple of dosing frequencies of HP802-247, when coordinated with standard care, in comparison with control plus standard care, in healing venous leg ulcers over a 12-week therapy period. The research was a randomized, double blind, dose-finding survey involving 228 topics enrolled across 35 investigational centers in the United States.

Overall, HP802-247 accomplished statistical significance, in contrast with control plus standard care, in each the primary and secondary endpoints. HP802-247 was usually well put up within the study with more frequently confirmed adverse events being skin ulcers, cellulitis, ended infection, and skin irritability. The security profile as to the active groups was identical to the vehicle control.